The Inhibitory Effect of Dopamine Agonists on LH Release in Women1

Abstract

Our demonstration of an inhibitory effect of dopamine on LH release prompted us to examine whether a similar action exists for dopamine agonists, such as L-dopa and 2-bromo-α-ergocryptine (CB-154). Following the administration of L-dopa (0.5 g, orally) to 6 normal women in the early follicular phase, a significant fall in mean LH levels after 1 h which lasted for 5 h was observed (P < 0.00005). This was followed by a significant rebound above basal levels between the 7th and 10th h (P < 0.00005). The expected fall in mean PRL levels which lasted for 4 h (P < 0.00001) was followed by a significant rebound above basal levels after the 6th h (P < 0.00001). There was no significant change in mean FSH levels. Following the administration of CB-154 (2.5 mg, orally) to 6 women with hyperprolactinemic amenorrhea, there was also a significant fall in LH levels (P < 0.00001) and in FSH levels (P < 0.00001) from 5 h until the study ended at 10 h. The anticipated PRL suppression was also observed and persisted for the duration of the 10 h study. The demonstration of an inhibitory effect of L-dopa and CB-154 on LH release adds further support to the role of dopaminergic control of pituitary LH secretion.